ReviewBritish journal of pharmacology2020
Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.
Review in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 103 citations in OpenAlex.
- Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double-blind study: New insights on TARC, CTACK, TSLP, and E-selectin.Immunity, inflammation and disease · 2024Trial
- Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19.Frontiers in cellular and infection microbiology · 2022Trial
- Gut microbiota in chronic inflammation: the interplay with lipid mediators.Gut microbes · 2026Review
- NSAIDs in the environment: a 2020-2025 review of impacts on plant and algal Physiology.Ecotoxicology (London, England) · 2026Review
- Intentional pediatric nonprescription cold/cough and analgesic/antipyretic exposure trends amid the COVID-19 pandemic.Clinical toxicology (Philadelphia, Pa.) · 2026Article
- Immunomodulatory strategies for managing cytokine storms in chronic COVID: mechanisms, therapeutic targets, and clinical advances.Annals of medicine and surgery (2012) · 2026Review
- A descriptive multilevel analysis associating COVID-19 with polymyositis: from genetic markers and candidate mediators to clinical hematological profiles.Frontiers in medicine · 2026Article
- Corticosteroids or NSAIDs in Managing Acute Respiratory Infections: Valuable Differences.Journal of immunology research · 2026Review
- Trends in US Pediatric Unintentional Nonprescription Cold and Cough, Analgesic and Antipyretic Drug Exposure Cases amid the COVID-19 Pandemic.Clinical drug investigation · 2025Article
- A versatile attention-based neural network for chemical perturbation analysis and its potential to aid surgical treatment: an experimental study.International journal of surgery (London, England) · 2024Article
- Diverse roles of SARS-CoV-2 Spike and Nucleocapsid proteins in EndMT stimulation through the TGF-β-MRTF axis inhibited by aspirin.Cell communication and signaling : CCS · 2024Article
- Unraveling the Mechanism of Xiaochaihu Granules in Alleviating Yeast-Induced Fever Based on Network Analysis and Experimental Validation.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Pulmonary endothelium-targeted nanoassembly of indomethacin and superoxide dismutase relieves lung inflammation.Acta pharmaceutica Sinica. B · 2023Article
- Patterns of Opioid and Non-Opioid Analgesic Consumption in Patients with Post-COVID-19 Conditions.Journal of clinical medicine · 2023Article
- Novel Molecular Consortia of Cannabidiol with Nonsteroidal Anti-Inflammatory Drugs Inhibit Emerging Coronaviruses' Entry.Pathogens (Basel, Switzerland) · 2023Article
- Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study.Scientific reports · 2023Article
- Neutrophil elastase: From mechanisms to therapeutic potential.Journal of pharmaceutical analysis · 2023Review
- Neuroinflammatory Response in Reward-Associated Psychostimulants and Opioids: A Review.Cellular and molecular neurobiology · 2023Review
- Metabolic regulation by prostaglandin EAllergy · 2023Article
- Trends in pediatric nonprescription analgesic/antipyretic exposures during the COVID-19 pandemic.Clinical toxicology (Philadelphia, Pa.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the novel coronavirus disease 2019 (COVID-19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine or efficient treatment strategies against COVID-19. Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain, and inflammation (common symptoms of COVID-19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxyganase enzymes. PGs can exert either proinflammatory or anti-inflammatory effects depending on the inflammatory scenario. In this review, we survey the potential roles that NSAIDs and PGs may play during SARS-CoV-2 infection and the development and progression of COVID-19. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.